STOCK TITAN
  1. Home
  2. News
  3. GOVXW

Geovax Labs Inc - GOVXW STOCK NEWS

Welcome to our dedicated news page for Geovax Labs (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on Geovax Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geovax Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geovax Labs's position in the market.

News
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) will report its third quarter 2023 financial results on November 8, 2023, after the close of U.S. markets. The company will host a live conference call and webcast at 4:30 p.m. ET to provide a corporate update and discuss financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
News
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
Rhea-AI Summary
GeoVax Labs has commenced the planned site expansion for the Phase 2 clinical trial of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, in immunocompromised patients. The trial will enroll patients at multiple medical centers across the United States. The Phase 2 trial aims to evaluate the safety and immunogenicity of GEO-CM04S1 compared to Pfizer/BioNTech or Moderna mRNA-based vaccines in patients with hematologic malignancies who have received stem cell transplants or CAR T cell therapy. GeoVax believes that GEO-CM04S1 has the potential to offer a more robust and durable degree of protection for immunocompromised patients and as a booster vaccine for healthy individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial covid-19
-
News
GeoVax to Participate in Upcoming November Investor and Industry Events
Rhea-AI Summary
GeoVax Labs, Inc. to participate in four investor and industry events in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
conferences
News
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
Rhea-AI Summary
GeoVax Labs, Inc. provides an update on key strategic initiatives, including advancements in their COVID-19 vaccine clinical programs and cancer therapy program. They have also received new patents for their vaccines. Initial data readouts from clinical trials are expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
News
GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
Rhea-AI Summary
GeoVax Labs receives patent allowance for Marburg virus vaccine, demonstrating 80% survival in nonhuman primate studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
News
GeoVax Receives Notice of Allowance for HIV Vaccine Patent
Rhea-AI Summary
GeoVax Labs receives Notice of Allowance for patent application on HIV vaccine boost compositions and methods of use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
News
GeoVax to Participate in Upcoming October Investor and Industry Events
Rhea-AI Summary
GeoVax Labs, Inc. will provide updates on Phase 2 clinical trials for their COVID-19 vaccine and cancer immunotherapy programs. The Chairman and CEO will participate in upcoming investor and industry events, including the Emerging Growth Virtual Conference, BioFuture 2023, and Dawson James Small Cap Growth Conference. A live webcast of the Dawson James presentation will be available on GeoVax's website. One-on-one meetings with management will also be available at the conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Rhea-AI Summary
GeoVax Labs and ProBioGen sign a commercial license agreement for ProBioGen's AGE1.CR.pIX suspension cell line, enhancing GeoVax's vaccine manufacturing capabilities. The cell line enables high-yield and scalable production, leading to cost-effectiveness and increased productivity. It supports a wide range of viruses and vaccine types, improving suitability for various vaccines in development. The partnership aims to accelerate vaccine production and distribution, benefiting communities worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
Rhea-AI Summary
Preclinical data for GEO-CM02 demonstrates single-dose protection against multiple SARS-CoV-2 variants. GEO-CM02 vaccine induces immune responses against original Wuhan strain and Omicron variant. Vaccine significantly reduces inflammation and immunopathology in vaccinated animals' lungs. Vaccines designed to induce both antibodies and T-cells can address viral variation and escape. GeoVax evaluating similar vaccine design in three Phase 2 clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
covid-19
News
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
Rhea-AI Summary
GeoVax Labs, Inc. publishes data from Phase 2 trial of GEO-CM04S1 COVID-19 vaccine, showing high immunogenicity in immunocompromised patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
covid-19
Stock GOVXW logo
Geovax Labs Inc

Nasdaq:GOVXW

GOVXW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

GOVXW Stock Data

1.89M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Smyrna

About GOVXW

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.